These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 10628593

  • 1. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
    Schoenfeld P.
    Am J Med; 1999 Dec 13; 107(6A):48S-54S. PubMed ID: 10628593
    [Abstract] [Full Text] [Related]

  • 2. Meloxicam: selective COX-2 inhibition in clinical practice.
    Furst DE.
    Semin Arthritis Rheum; 1997 Jun 13; 26(6 Suppl 1):21-7. PubMed ID: 9219316
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D, Heeley E, Hughes K, Shakir SA.
    Rheumatology (Oxford); 2003 May 13; 42(5):622-31. PubMed ID: 12709537
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
    Dequeker J, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, Isomäki H, Littlejohn G, Mau J, Papazoglou S.
    Br J Rheumatol; 1998 Sep 13; 37(9):946-51. PubMed ID: 9783758
    [Abstract] [Full Text] [Related]

  • 7. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wallace JL.
    Am J Med; 1999 Dec 13; 107(6A):11S-16S; discussion 16S-17S. PubMed ID: 10628589
    [Abstract] [Full Text] [Related]

  • 8. Rationalizing cyclooxygenase inhibition for optimization of efficacy and safety profiles. Proceedings of a workshop. Fort Worth, Texas, USA. February 1999.
    Am J Med; 1999 Dec 13; 107(6A):1S-89S. PubMed ID: 10628587
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
    MacDonald TM, Pettitt D, Lee FH, Schwartz JS.
    Rheumatology (Oxford); 2003 Nov 13; 42 Suppl 3():iii3-10. PubMed ID: 14585912
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 13; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety of meloxicam: a global analysis of clinical trials.
    Distel M, Mueller C, Bluhmki E, Fries J.
    Br J Rheumatol; 1996 Apr 13; 35 Suppl 1():68-77. PubMed ID: 8630641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.